Nektar Therapeutics (NKTR) Price Target Increased to $103.00 by Analysts at Mizuho

Nektar Therapeutics (NASDAQ:NKTR) had its target price upped by Mizuho from $89.00 to $103.00 in a research note released on Friday, MarketBeat Ratings reports. Mizuho currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts also recently weighed in on NKTR. Canaccord Genuity reiterated a buy rating and issued a $80.00 target price (up from $50.00) on shares of Nektar Therapeutics in a research note on Wednesday, January 10th. Jefferies Group lifted their target price on Nektar Therapeutics from $2.12 to $88.00 and gave the company a buy rating in a research note on Tuesday, January 16th. Cowen reiterated a buy rating and issued a $101.00 target price on shares of Nektar Therapeutics in a research note on Friday, March 2nd. Zacks Investment Research downgraded Nektar Therapeutics from a hold rating to a sell rating in a research note on Tuesday, January 9th. Finally, HC Wainwright reiterated a buy rating and issued a $125.00 target price on shares of Nektar Therapeutics in a research note on Monday, April 2nd. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Nektar Therapeutics presently has an average rating of Buy and an average price target of $63.75.

How to Become a New Pot Stock Millionaire

NASDAQ:NKTR opened at $93.87 on Friday. The company has a market cap of $15,105.84, a P/E ratio of -170.67 and a beta of 1.74. The company has a current ratio of 5.82, a quick ratio of 5.63 and a debt-to-equity ratio of 2.79. Nektar Therapeutics has a 52-week low of $17.33 and a 52-week high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.14. The firm had revenue of $95.47 million for the quarter, compared to the consensus estimate of $36.96 million. Nektar Therapeutics had a negative return on equity of 156.85% and a negative net margin of 31.42%. The firm’s quarterly revenue was up 154.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.28) EPS. research analysts expect that Nektar Therapeutics will post -1.33 EPS for the current fiscal year.

In related news, SVP Stephen K. Doberstein sold 2,426 shares of Nektar Therapeutics stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $82.94, for a total value of $201,212.44. Following the sale, the senior vice president now directly owns 67,394 shares in the company, valued at $5,589,658.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO John Nicholson sold 220,144 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $99.27, for a total value of $21,853,694.88. Following the completion of the sale, the chief operating officer now owns 267,657 shares in the company, valued at $26,570,310.39. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 369,592 shares of company stock worth $34,241,981. Company insiders own 6.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of the stock. Crossmark Global Holdings Inc. boosted its stake in shares of Nektar Therapeutics by 2.8% in the fourth quarter. Crossmark Global Holdings Inc. now owns 30,168 shares of the biopharmaceutical company’s stock valued at $1,802,000 after buying an additional 829 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Nektar Therapeutics by 6.3% in the fourth quarter. Amalgamated Bank now owns 21,775 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 1,298 shares in the last quarter. Flinton Capital Management LLC boosted its stake in shares of Nektar Therapeutics by 20.6% in the fourth quarter. Flinton Capital Management LLC now owns 10,976 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 1,872 shares in the last quarter. Thrivent Financial For Lutherans boosted its stake in shares of Nektar Therapeutics by 2.0% in the fourth quarter. Thrivent Financial For Lutherans now owns 97,655 shares of the biopharmaceutical company’s stock valued at $5,832,000 after buying an additional 1,925 shares in the last quarter. Finally, BB&T Investment Services Inc. purchased a new stake in shares of Nektar Therapeutics in the fourth quarter valued at approximately $119,000. Hedge funds and other institutional investors own 96.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Nektar Therapeutics (NKTR) Price Target Increased to $103.00 by Analysts at Mizuho” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3342872/nektar-therapeutics-nktr-price-target-increased-to-103-00-by-analysts-at-mizuho.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.